UAB has established an interdisciplinary hub for research and patient care in the study of immunity.
The discovery of new possible biomarkers to predict clinical and immune responses to dengue virus infection could be critical to informing future vaccines for the mosquito-borne virus, which saw a record number of over 400 million cases in 2019.
Israel’s Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.
On Dec. 17, a U.S. Food and Drug Administration panel is expected to review the data on the Moderna COVID-19 vaccine, paving the way for approval. Researchers at the George Washington University led one of the 100 clinical sites testing…
GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil’s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.
Rutgers’ principal investigator for the Moderna phase 3 coronavirus vaccine clinical trial at Rutgers New Jersey Medical School is available to discuss the drugmaker’s vaccine, which the company has announced is 94.5 percent effective. Moderna intends to seek an emergency…
A team from Seattle Children’s Research Institute has developed an improved mouse model for tuberculosis that replicates characteristics of the human disease not possible in other available models. The ultra-low dose model, named that because mice are infected with 1-3…
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
A team of researchers at the University of Chicago have developed a self-assembling nanoparticle to create a toolbox for treating infections such as Toxoplasma gondii, a serious parasitic infection.
Scientists are planning for Phase 1 human trials of a vaccine they developed by using CRISPR gene-editing technology to mutate the parasite that causes leishmaniasis, a skin disease common in tropical regions of the world and gaining ground in the United States.
A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.
Better understanding of the surface chemistry of the SARS-CoV-2 virus is needed to reduce transmission and accelerate vaccine design.
A new study at the University of Chicago and Duke University finds that a new type of intranasal vaccine induces a strong immune response in lungs, with possible implications for COVID-19. The system uses nanofibers tagged with antigens to prime the immune system against a potential invasion.
Like a scene out of “Invasion of the Body Snatchers,” a virus infects a host and converts it into a factory for making more copies of itself.
The COVID-19 pandemic demands action on many fronts, from prevention to testing to treatment. Not content to focus its research efforts on just one, the laboratory of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University is tackling the problem from seven different angles.
The coronavirus pandemic has been unprecedented in its impact, leaving no aspect of life unaffected from its arrival in late 2019. From day-to-day impacts on work, school, social gatherings, and travel, to larger shockwaves to the world’s economy and health…
Supriya Munshaw, a senior lecturer at Johns Hopkins Carey Business School, offers insights on the likely time frame for a coronavirus vaccine, the steps involved in developing one, the most promising candidates currently in the labs of biotech companies, and why, years after the MERS and SARS outbreaks, a coronavirus vaccine still has not been produced.
The National Institutes of Health has awarded Tulane National Primate Research Center a contract of up to $10.3 million to evaluate vaccines and treatments to combat coronavirus disease 2019.
Researchers and faculty from multiple disciplines across the University of Kentucky are coming together as part of the global effort to treat, understand and eradicate COVID-19. A new workgroup within UK’s College of Medicine is bringing together experts from across the campus to focus on advising COVID-19 patient care and clinical trials based on emerging research and potential treatment options.
The Department of Energy has a vital role to play in the national response to COVID-19. Researchers have already used tools at national laboratories to make major inroads to analyzing the virus and its spread.
From working to develop one of the first nonhuman primate models for the 2019 novel coronavirus disease (COVID-19) to designing new nanotechnology-based tests to rapidly diagnose infections, researchers at Tulane University are responding across disciplines to the emerging coronavirus epidemic.